ICBcomb

ICBcomb compiles and standardizes gene expression and immune-infiltration data from immune checkpoint blockade (ICB) combination therapy studies to enable comparative analyses across cancer types and treatment regimens.

Key Features:

• Extensive Data Collection: Compiles 1,399 samples across 29 cancer types and 52 drugs from human and mouse ICB combination therapy studies.
• Comparative Group Analysis: Enables direct comparisons of expression profiles and enrichment results between groups treated with ICB, other therapeutic agents, or combination therapies.
• Expression Profiling: Provides dataset- and disease-level expression profiles and enrichment results for comparative analyses.
• Gene-Level Analysis: Supports gene-centric comparisons across datasets and disease contexts for specified gene symbols.
• Gene Set Analysis: Performs Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) using built-in and user-supplied gene sets.
• Immune Cell Infiltration Analysis: Quantifies and compares the abundance of immune cell types between different treatment groups.

Scientific Applications:

• Mechanistic Studies: Dissects molecular mechanisms underlying responses to ICB combination therapies using differential expression and enrichment analyses.
• Biomarker and Combination Discovery: Supports identification of candidate combinatory drugs and biomarkers through cross-treatment and cross-cancer comparisons.
• Immune Landscape Characterization: Characterizes treatment-associated changes in immune cell infiltration across cohorts and therapies.
• Translational and Clinical Research Support: Provides comparative expression and immune-infiltration evidence to inform translational studies and clinical trial design.

Methodology:

Compilation and analysis of human and mouse gene expression data from ICB combination therapy studies with between-group comparisons and gene set analyses using GSVA and GSEA.